These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 9725776

  • 1. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF, D'Haese PC, Lamberts LV, Djukanovic L, Pejanovic S, Goodman WG, De Broe ME.
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [Abstract] [Full Text] [Related]

  • 2. Factors influencing serum aluminum in CAPD patients.
    Montenegro J, Aguirre R, Saracho R, Moina I, Martínez I.
    Clin Nephrol; 1998 Aug; 50(2):77-83. PubMed ID: 9725777
    [Abstract] [Full Text] [Related]

  • 3. Competition of iron and aluminum for transferrin: the molecular basis for aluminum deposition in iron-overloaded dialysis patients?
    Van Landeghem GF, D'Haese PC, Lamberts LV, De Broe ME.
    Exp Nephrol; 1997 Aug; 5(3):239-45. PubMed ID: 9208284
    [Abstract] [Full Text] [Related]

  • 4. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A, Karkar A, Abdelrahman M.
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [Abstract] [Full Text] [Related]

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 6. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT, Milliner DS, Johnson WJ.
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [Abstract] [Full Text] [Related]

  • 7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 8. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, Fagalde A, Barsoum RS, Lamberts LV, De Broe ME.
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [Abstract] [Full Text] [Related]

  • 9. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A, von Herrath D, Schaefer K.
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [Abstract] [Full Text] [Related]

  • 10. Intravenous iron supplementation in children on hemodialysis.
    Leijn E, Monnens LA, Cornelissen EA.
    J Nephrol; 2004 Dec; 17(3):423-6. PubMed ID: 15365964
    [Abstract] [Full Text] [Related]

  • 11. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G, Hörl WH.
    Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
    [Abstract] [Full Text] [Related]

  • 12. The effect of iron stores on corrected QT dispersion in patients undergoing peritoneal dialysis.
    Wu VC, Huang JW, Wu MS, Chin CY, Chiang FT, Liu YB, Wu KD.
    Am J Kidney Dis; 2004 Oct; 44(4):720-8. PubMed ID: 15384024
    [Abstract] [Full Text] [Related]

  • 13. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F.
    J Nephrol; 2000 Oct; 13(6):444-9. PubMed ID: 11132761
    [Abstract] [Full Text] [Related]

  • 14. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC, Hung SC, Tarng DC.
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [Abstract] [Full Text] [Related]

  • 15. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
    Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, Kobold U, Mayer G.
    Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
    [Abstract] [Full Text] [Related]

  • 16. Serum ferritin and tissue iron in anemic dialysis patients.
    Bárány P, Eriksson LC, Hultcrantz R, Pettersson E, Bergström J.
    Miner Electrolyte Metab; 1997 Oct; 23(3-6):273-6. PubMed ID: 9387132
    [Abstract] [Full Text] [Related]

  • 17. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R.
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [Abstract] [Full Text] [Related]

  • 18. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M, Sipilä R, Pitkänen E.
    Scand J Urol Nephrol Suppl; 1990 May; 131():49-54. PubMed ID: 2075470
    [Abstract] [Full Text] [Related]

  • 19. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Joffe P, Olsen F, Heaf JG, Gammelgaard B, Pödenphant J.
    Clin Nephrol; 1989 Sep; 32(3):133-8. PubMed ID: 2791364
    [Abstract] [Full Text] [Related]

  • 20. Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease.
    Parisien M, Charhon SA, Arlot M, Mainetti E, Chavassieux P, Chapuy MC, Meunier PJ.
    J Bone Miner Res; 1988 Jun; 3(3):259-67. PubMed ID: 3213621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.